



# FINANCIAL TEAR SHEET

## Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

## Primary IR

### Contact

Bob Yedid  
LifeSci Advisors  
Phone: 646-597-6989  
Fax: 516-428-8577  
E-mail:  
Bob@lifesciadvisors.com

## Stock Information

PTX.O (Common Stock)

|                    |                    |
|--------------------|--------------------|
| Exchange           | NASDAQ (US Dollar) |
| Price              | \$2.83             |
| Change (%)         | ▲ 0.07 (2.54%)     |
| Volume             | 68,589             |
| 52 Week Low        | \$1.83             |
| Market Cap         | \$31,829,487       |
| Rolling EPS        | -17.00             |
| PE Ratio           | 0                  |
| Shares Outstanding | 11,532,423         |

Data as of 10/20/17 3:59 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Press Releases & Upcoming Events

October 17, 2017 - 4:06 p.m.

Pernix Therapeutics Announces Planned

Departure of Chief Financial Officer

July 27, 2017 - 4:03 p.m.

Pernix Therapeutics Reports Second Quarter

2017 Financial Results and Provides Business

Update

July 20, 2017 - 4:54 p.m.

Pernix Commences Refinancing Transactions to

Fortify Balance Sheet

There are currently no events scheduled.

## SEC Filings

| Filing Date | Form    |
|-------------|---------|
| 10/17/17    | 8-K     |
| 09/27/17    | DEFA14A |
| 09/27/17    | DEF 14A |
| 09/22/17    | 8-K     |

## Corporate Governance

|                    |   |
|--------------------|---|
| John Sedor         | Chairman of the Board and CEO   |
| Graham Miao        | President and CFO   |
| Kenneth R. Piña    | Senior Vice President, Chief<br>Legal & Compliance Officer and<br>Corporate Secretary |
| George<br>P. Jones | Vice President of Sales and<br>Marketing  |
| Angus Smith        | Vice President, Business<br>Development & Strategic<br>Planning                       |